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We thank Meijers and Evenepoel1 for their comments in
‘Targeting hyperphosphatemia: truth or dare.’ We agree
that the most desirable study of phosphorus binders on
dialysis is a blinded, placebo-controlled randomized trial.
We also agree that challenging existing paradigms is
essential, especially when those paradigms themselves are
based largely on expert opinion, as in the case for serum
phosphate targets on dialysis. Unfortunately, however,
practical considerations must often prevail over ideal
theory to force compromises in the interest of progress.
In our opinion, the use of phosphorus binders on dialysis
is one example where such concessions may need to be
made. We would eagerly support and participate in a
double-blinded placebo-controlled study if it was proven
that recruitment and retention of participants was feasible
in the real world. We are skeptical, however, given the
widespread view among nephrologists that control of
phosphate is the most important aspect of the manage-
ment of mineral metabolism on dialysis. This attitude
would lead to preferential withdrawal of participants from
the placebo arm in the event of severe hyperphosphatemia.
With limited research resources and numerous questions
to be answered, the risk of failure of the ‘perfect’
phosphorus binder study on dialysis due to poor enroll-
ment, limited power, and bias would be unacceptably high.
At the crossroads of theory and practice, we believe that a
trial of more- versus less-intensive phosphate control will
present a far greater chance for operational success and
will yield critically important results that would be readily
transferable into practice. Regardless of how the nephrol-
ogy community ultimately proceeds, we are excited that
our blueprint has initiated a much-required dialogue
exemplified by the comments made by Meijers and
Evenepoel.
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To the Editor: Chevalier’s stimulating commentary1 refers to
the report that nearly 50% of children with a solitary kidney
in the setting of congenital anomalies of the kidney and
urinary tract (CAKUTs) would be receiving dialysis by
30 years of age.2
The Commentary states that the ‘fundamental differences
between the long-term outcomes of patients with congenital
solitary kidney and those of healthy adults undergoing
unilateral nephrectomy as renal transplant donors, who have
no increased risk for renal failure’ are nephron endowment
below the median, and the consequences of the compensatory
growth, such as glomerular hyperfiltration, hypertension, and
proteinuria, with the additional risks of progression, includ-
ing infection, hypoxia, and nephrotoxicity.
However, another possibility to be considered is the case
of a solitary sick kidney with genetically determined
microscopic defects such as glomerulocystic alterations,
glomerulomegalia, and small tubular ectasia belonging to
the large phenotypic spectrum of mutations in the hepato-
cyte nuclear factor-1b (HNF-1b), controlling the transcrip-
tion of genes expressed in the tubular epithelial cells,
including UMOD, Pkhd1, Pkd2, and Socs3 during kidney
development (Figure 1).3–5
A child with only one kidney and mutation in the HNF-1b
gene will have a natural story that is ineluctably irreversible and
leads to end-stage renal failure, and is therefore different from
that of other children with only one kidney or adult renal living
donors, even if they are exposed to similar risk factors.
Therefore, in the present era, looking toward biomarker
discovery and gene therapy, ‘monitoring children with
CAKUT ‘..not only..’ involves monitoring diet, y blood
pressure, etc.’,1 but also genetic evaluation including HNF-1b
gene mutation.
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